DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0090-9556/04/3203-314-320$20.00
DMD 32:314-320, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ghosal, A.
Right arrow Articles by Zbaida, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ghosal, A.
Right arrow Articles by Zbaida, S.

IDENTIFICATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE ENZYME(S) RESPONSIBLE FOR THE GLUCURONIDATION OF EZETIMIBE (ZETIA)

Anima Ghosal, Neil Hapangama, Yuan Yuan, Joana Achanfuo-Yeboah, Robert Iannucci, Swapan Chowdhury, Kevin Alton, James E. Patrick, and Shmuel Zbaida

Drug Metabolism and Pharmacokinetics, Schering-Plough Research Institute, Kenilworth, New Jersey

Ezetimibe [1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone] (Zetia; Schering-Plough, Kenilworth, NJ) is the first in a new class of cholesterol-lowering agents known as cholesterol absorption inhibitors. The objective of this study was to identify the isoform(s) of human liver and intestinal UDP-glucuronosyltransferase (UGT) enzymes responsible for the glucuronidation of ezetimibe. The main circulating metabolite of this drug in human plasma is SCH 60663, the phenolic glucuronide conjugate of ezetimibe. SCH 60663 [m/z = 584 Thompsons (Th)] is also the major in vitro metabolite formed by human liver microsomes supplemented with UDP glucuronic acid (UDPGA). In contrast to the liver, human jejunum microsomes supplemented with UDPGA converted ezetimibe to two glucuronides with the same mass (m/z = 584 Th) by liquid chromatography-mass spectrometry. One corresponds to the phenolic glucuronide (1-O-[4-trans-2S,3R)-1-(4-fluorophenyl)-4-oxo-3-[3(S)-hydroxy-3-(4-fluorophenyl)propyl]-2-azetidinyl]phenyl-ß-D-glucopyranuronic acid; SCH 60663) and the other was identified as the benzylic glucuronide of ezetimibe (1-O-[1(S)-(4-fluorophenyl)-3-[1-(4-fluorophenyl)-2(S)-(4-hydroxyphenyl)-4-oxo-3(R)-azetidinyl]propyl]-ß-D-glucopyranuronic acid; SCH 488128). Recombinant human UGT1A1, UGT1A3, and UGT2B15 all exhibited catalytic activity with respect to the formation of the phenolic glucuronide. However, UGT2B7 exclusively formed SCH 488128, a trace metabolite detected in dog and human plasma samples after oral administration of ezetimibe. In conclusion, the formation of SCH 60663 is mediated via UGT1A1, UGT1A3, and UGT2B15, and the formation SCH 488128 is mediated via UGT2B7.


Address correspondence to: Dr. Anima Ghosal, Drug Metabolism and Pharmacokinetics, Schering-Plough Research Institute, 2015 Galloping Hill Road, K-15-1945, Kenilworth, NJ 07033. E-mail: anima.ghosal{at}spcorp.com




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
T. Yamamoto, K. Ito, M. Honma, T. Takada, and H. Suzuki
Cholesterol-Lowering Effect of Ezetimibe in Uridine Diphosphate Glucuronosyltransferase 1A-Deficient (Gunn) Rats
Drug Metab. Dispos., September 1, 2007; 35(9): 1455 - 1458.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Oswald, S. Westrup, M. Grube, H. K. Kroemer, W. Weitschies, and W. Siegmund
Disposition and Sterol-Lowering Effect of Ezetimibe in Multidrug Resistance-Associated Protein 2-Deficient Rats
J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1293 - 1299.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
A. J. Bergman, J. Burke, P. Larson, A. O. Johnson-Levonas, L. Reyderman, P. Statkevich, S. E. Maxwell, T. Kosoglou, G. Murphy, K. Gottesdiener, et al.
Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients.
J. Clin. Pharmacol., March 1, 2006; 46(3): 328 - 336.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
S. L Koshman, L. D Lalonde, I. Burton, W. J Tymchak, and G. J Pearson
Supratherapeutic Response to Ezetimibe Administered with Cyclosporine
Ann. Pharmacother., September 1, 2005; 39(9): 1561 - 1565.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
H. Kaji and T. Kume
REGIOSELECTIVE GLUCURONIDATION OF DENOPAMINE: MARKED SPECIES DIFFERENCES AND IDENTIFICATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE ISOFORM
Drug Metab. Dispos., March 1, 2005; 33(3): 403 - 412.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.